The genetics of type 2 diabetes and its clinical relevance
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The increasing worldwide prevalence of type 2 diabetes (T2D) motivates efforts to use genetics to define key pathways involved in disease predisposition, and thereby to improve management of the disease. Research over the past 5 years has taken the total number of genetic loci implicated in T2D susceptibility beyond 60, and the emphasis is now shifting to the translation of these genetic insights into clinical value. Clinical translation may flow from the identification of novel therapeutic targets, but opportunities also exist with respect to individual prediction, diagnostic biomarkers and therapeutic optimization. To date, the main clinical impact has been seen for relatively rare, monogenic forms of diabetes rather than common T2D. However, the advent of high throughput sequencing approaches may herald discovery of rare and low frequency variants that offer greater translational potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
A genome-wide association study identifies novel risk loci for type 2 diabetes
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007) · Nature · doi:10.1038/nature05616 · Cited by 2,993
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287 · cited 1×
“The first round of GWAS in 2007 confirmed known loci at PPARG , KCNJ11 and near TCF7L2 (first identified ahead of the GWAS era by detailed association analysis of a previously demonstrated linkage signal on chromosome 10q (9)), in addition to revealing novel loci including signals near CDKAL1 , HHEX , SLC30A8 , IGF2BP…”
BackgroundReplication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Self-citationNew genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
DIAGRAM Consortium, Dupuis, J., GIANT Consortium, Global BPgen Consortium, Anders Hamsten on behalf of Procardis Consortium, the MAGIC investigators, Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., et al. (2010) · Nature Genetics · doi:10.1038/ng.520 · Cited by 2,166 · cited 3×
“Whilst these data have provided clues to several aspects of T2D pathogenesis – such as the relationship between T2D, insulin secretion, obesity and insulin resistance (15, 18) – the dividend in terms of precise mechanistic insights has been relatively limited.”
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Morris, A. P., Voight, B. F., Teslovich, T. M., Ferreira, T., Segrè, A. V., Steinthorsdottir, V., Strawbridge, R. J., Khan, H., Grallert, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2383 · Cited by 1,912 · cited 8×
“Optimal treatments for monogenic diabetes by subtype Monogenic diabetes subtype Distinguishing clinical features Examples of causal genes Optimal treatment Examples of more common subtypes GCK-MODY Mild fasting hyperglycaemia GCK Diet alone HNF1A-MODY Young onset diabetes HNF1A Low dose sulphonylurea Neonatal diabetes…”
BackgroundInfluentialSelf-citationThe Finnish Diabetes Prevention Study (DPS)
Lindström, J., Louheranta, A., Mannelin, M., Rastas, M., Salminen, V., Eriksson, J., Uusitupa, M., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3230 · Cited by 1,848
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
Altshuler, D., Hirschhorn, J. N., Klannemark, M., Lindgren, C. M., Vohl, M.-C., Nemesh, J., Lane, C. R., Schaffner, S. F., Bolk, S., Brewer, C., et al. (2000) · Nature Genetics · doi:10.1038/79216 · Cited by 1,766
The mystery of missing heritability: Genetic interactions create phantom heritability
Zuk, O., Hechter, E., Sunyaev, S. R., & Lander, E. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119675109 · Cited by 1,542 · cited 1×
“In addition, it seems likely that estimates of T2D heritability may have been incorrectly specified perhaps because of epigenetic effects (as a cause of familial aggregation masquerading as heritability) or complex epistatic interactions (100).”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“Although this study provides some functional support for ATM being the causal gene at this locus [ATM inhibition led to reduced metformin stimulated phosphorylation of AMP-activated protein kinase (AMPK)], others have shown that the insulin sensitizing effects of metformin may be AMPK independent (88) or that, in cert…”
BackgroundThe Regulation of INK4/ARF in Cancer and Aging
Kim, W. Y., & Sharpless, N. E. (2006) · Cell · doi:10.1016/j.cell.2006.10.003 · Cited by 1,009 · cited 1×
“These are well-recognized tumour suppressor genes: germline CDKN2A mutations are a cause of familial melanoma syndromes and somatic CDKN2A or CDKN2B are amongst the genes most often disrupted by somatic mutations in cancer (41).”
Backgroundp16INK4a induces an age-dependent decline in islet regenerative potential
Krishnamurthy, J., Ramsey, M. R., Ligon, K. L., Torrice, C., Koh, A., Bonner-Weir, S., & Sharpless, N. E. (2006) · Nature · doi:10.1038/nature05092 · Cited by 1,003 · cited 1×
“Rodent data are consistent with a role in glucose homeostasis: overexpression of cdkn2a and knockout of cdk4 , a biochemical target of the cyclin-dependent kinase inhibitosr encoded by Cdkn2a and cdkn2b, leads to islet hypoplasia and a T2D-like phenotype (42, 43).”
BackgroundSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988 · cited 1×
“For instance, for patients with diabetes due to HNF1A mutations, sensitivity to the effects of sulphonylureas (82) makes low dose treatment with that class of drugs the first choice; and, for some children with early onset diabetes, a molecular diagnosis of neonatal diabetes due to mutations in KCNJ11 or ABCC8 , can e…”
BackgroundClinical risk factors, DNA variants, and the development of type 2 diabetes
Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Berglund, G., Altshuler, D., Nilsson, P., & Groop, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801869 · Cited by 938
Genotype score in addition to common risk factors for prediction of type 2 diabetes
Meigs, J. B., Shrader, P., Sullivan, L. M., McAteer, J. B., Fox, C. S., Dupuis, J., Manning, A. K., Florez, J. C., Wilson, P. W. F., D'Agostino, R. B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804742 · Cited by 759 · cited 2×
“The clinical value of current GWAS-identified loci has been investigated by the Framingham Offspring Study (63), the Malmö Preventive Project (MPP) and Botnia Study (64), amongst others (65, 66).”
BackgroundGloyn, A. L., Weedon, M. N., Owen, K. R., Turner, M. J., Knight, B. A., Hitman, G., Walker, M., Levy, J. C., Sampson, M., Halford, S., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.2.568 · Cited by 754
Self-citationLyssenko, V., Nagorny, C. L. F., Erdos, M. R., Wierup, N., Jonsson, A., Spégel, P., Bugliani, M., Saxena, R., Fex, M., Pulizzi, N., et al. (2009) · Nature Genetics · doi:10.1038/ng.288 · Cited by 742
Gudmundsson, J., Sulem, P., Steinthorsdottir, V., Bergthorsson, J. T., Thorleifsson, G., Manolescu, A., Rafnar, T., Gudbjartsson, D., Agnarsson, B. A., Baker, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2062 · Cited by 723
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700 · cited 1×
“Rodent data are consistent with a role in glucose homeostasis: overexpression of cdkn2a and knockout of cdk4 , a biochemical target of the cyclin-dependent kinase inhibitosr encoded by Cdkn2a and cdkn2b, leads to islet hypoplasia and a T2D-like phenotype (42, 43).”
BackgroundGenetic cause of hyperglycaemia and response to treatment in diabetes
Pearson, E. R., Starkey, B. J., Powell, R. J., Gribble, F. M., Clark, P. M., & Hattersley, A. T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14571-0 · Cited by 607
Recent Explosive Human Population Growth Has Resulted in an Excess of Rare Genetic Variants
Keinan, A., & Clark, A. G. (2012) · Science · doi:10.1126/science.1217283 · Cited by 548 · cited 1×
“Others would argue for a large contribution from low frequency and rare variants (98) especially given recent studies (99) showing the extent of rare and private variation in humans (a result of a rapid explosion in population growth in recent generations).”
BackgroundRung, J., Cauchi, S., Albrechtsen, A., Shen, L., Rocheleau, G., Cavalcanti-Proença, C., Bacot, F., Balkau, B., Belisle, A., Borch-Johnsen, K., et al. (2009) · Nature Genetics · doi:10.1038/ng.443 · Cited by 479
Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis
Diabetes Genetics Replication and Meta-analysis Consortium, Stahl, E. A., Myocardial Infarction Genetics Consortium, Wegmann, D., Trynka, G., Gutierrez-Achury, J., Do, R., Voight, B. F., Kraft, P., Chen, R., et al. (2012) · Nature Genetics · doi:10.1038/ng.2232 · Cited by 388 · cited 2×
“Recent studies suggest that a substantial part may be because of a long tail of additional loci that can be observed in GWAS data (19, 68).”
BackgroundRare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes
The Meta-Analysis of Glucose and Insulin-Related Traits Consortium (MAGIC), Bonnefond, A., Clément, N., Fawcett, K., Yengo, L., Vaillant, E., Guillaume, J.-L., Dechaume, A., Payne, F., Roussel, R., et al. (2012) · Nature Genetics · doi:10.1038/ng.1053 · Cited by 363
Self-citationJablonski, K. A., McAteer, J. B., de Bakker, P. I. W., Franks, P. W., Pollin, T. I., Hanson, R. L., Saxena, R., Fowler, S., Shuldiner, A. R., Knowler, W. C., et al. (2010) · Diabetes · doi:10.2337/db10-0543 · Cited by 271
Cancer and diabetes: are we ready for prime time?
Smith, U., & Gale, E. A. M. (2010) · Diabetologia · doi:10.1007/s00125-010-1815-8 · Cited by 73 · cited 1×
“Epidemiological evidence associating T2D and cancer has also gained recent impetus from the observation that anti-diabetes therapies may influence cancer risk (37).”
Background
Cited by
From big data analysis to personalized medicine for all: challenges and opportunities
Alyass, A., Turcotte, M., & Meyre, D. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0108-y · Cited by 557
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
“(GWAS) using high-density genotyping arrays have transformed understanding of the genetic architecture of T2D (7).”
BackgroundAli, O. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i4.114 · Cited by 350
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Saisho, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.109 · Cited by 263
Metadata
- Authors
- Pal, A., & McCarthy, M.
- Venue
- Clinical Genetics
- Publisher
- Wiley
- Published
- 2013-04
- Volume
- 83
- Issue
- 4
- Pages
- 297-306
- ISSN
- 0009-9163 (ISSN-L)
- 1399-0004
- OpenAlex
- W1896234937
- Cited by
- 52
- References
- 31
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.